

**NATIONAL INSTITUTE FOR HEALTH AND CARE
EXCELLENCE**

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Scoping

**STA - efanesoctocog alfa for treating and preventing
bleeding episodes in haemophilia A [ID6170]**

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

Stakeholders at scoping raised concerns that females who carry the haemophilia gene may have mild or, rarely, moderate to severe symptoms of bleeding and should not be excluded from accessing the technology. The NICE technical team also note that some factor VIII replacement treatments include blood products derived from humans, animals or animal cells. This may mean that some people are unable to have these products because of their religious faith or beliefs.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the committee?

The remit and population have been kept broad, to include all people with haemophilia A. It is noted that women with haemophilia A frequently have less severe symptoms, and that the clinical evidence for efanesoctocog alfa is from the XTEND-1 trial in which only people with severe haemophilia were enrolled. Where relevant, the committee should consider whether there is the potential for inequity of access based on gender in making its recommendations.

If appropriate the committee may consider the treatment options available for people who cannot have blood or animal products during guidance development.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

The remit and population have been kept broad and includes all people with haemophilia A. If evidence permits the following subgroups may be considered: severity of haemophilia, presence or development of inhibitors and previous treatment status; in doing so, any relevant equalities considerations should be explored.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?

None. The stakeholder group 'Hospital Information Services - Jehovah's Witnesses' is included on the stakeholder list.

Approved by Associate Director (name): Ian Watson

Date: 24/08/2023